Hepatitis C - Diagnosis and monitoring

Clinical Chemistry

Volumn 43, Issue 8 SUPPL., 1997, Pages 1507-1511

  Urdea, Mickey S ^a   Wuestehube, Linda J ^a   Laurenson, Patricia M ^a   Wilber, Judith C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ANTIGEN DETECTION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; PATIENT MONITORING; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

HEPATITIS C VIRUS;

EID: 0030792953     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.8.1507     Document Type: Conference Paper

References (22)

1. Bellentani S, Tiribelli C, Saccoccio G, Soddle M, Fratti N, De Martin C, Cristiani G. Prevalence of chronic liver diseases in the general population of northern Italy. Hepatology 1994;20:1442-9.
2. Murphy EL, Bryzman S, Williams AE, Co-Chien H, Schreiber GB, Ownby HE, et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996:275:995-1000.
3. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-64.
4. Ohno T, Lau JYN. The "gold-standard," accuracy, the current concepts: hepatitis C virus genotypes and viremia. Hepatology 1996;24:1312-5.
5. Lau JYN, Simmonds P, Urdea MS. Implications of the variation of the conserved region of hepatitis C virus genome. Lancet 1995;346:425-6.
6. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-95.
7. Damen M, Zaaijer HL, Cuypers HTM, Vrielink H, van der Poel CL, Reesink HW, Lelie PN. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995;35:745-9.
8. Dixit V, Quan S, Martin P, Larson D, Brezina M, DiNello R, et al. Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard genotyping methodologies. J Clin Microbiol 1995;33:2978-83.
9. Wilber JC, Polito A. Serological and virological diagnostic tests for hepatitis C virus infection. Semin Gastrointest Dis 1995;6:13-9.
10. Nowak MA, Bangham CRM. Population dynamics of immune responses to persistent viruses. Science 1996;272:74.
11. Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods 1996;58:175-85.
12. Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Berken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722-4.
13. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, et al. Accurate quantification of HCV RNA from all HCV genotypes using branched DNA (bDNA) technology. J Clin Microbiol 1996;34:901-7.
14. Kern D, Collins M, FultzT, Detmer J, Hamren S, Peterkin JJ, et al. An enhanced sensitivity branched DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996;34:3196-202.
15. Davis GL, Lau JYN. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. J Hepatol 1995;22:110-4.
16. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
17. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-15.
18. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol 1996;48:354-9.
19. Wilber JC. New developments in hepatitis C diagnostics and monitoring. Antiviral Ther 1996;1(Suppl 3):48-52.
20. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA with a solidphase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferontreated patients. Hepatology 1994;19:1337-41.
21. lino S, Hino K, Yasuda K. Current state of interferon therapy for chronic hepatitis C. Intervirology 1994;37:87-100.
22. Arase Y, Kumada H, Chayama K, Naoya M, Tsubota A, Koida l, et al. Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C. Int Hepatol Commun 1995;4:19-25.